For the third quarter of 2026, analysts expect Cartesian Therapeutics to report consensus revenue of approximately $0.16 million and an EPS loss of $1.02, while the stock trades around $6.34 compared to a $36.75 average price target. Investors are primarily focused on the enrollment progress and anticipated clinical milestones for the Phase 3 AURORA trial of lead candidate Descartes-08 in Myasthenia Gravis.
Recent pipeline updates include the initiation of the Phase 2 TRITON trial for myositis and expected preliminary data in systemic lupus erythematosus by year-end. With a cash position of approximately $149 million reported as of mid-2026, the company maintains an operational runway into 2028 to support its transition into a late-stage clinical organization.